Every 10-Q that BIOTRICITY INC (BTCY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BTCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTCY filings page.
Biotricity Inc. (BTCY) reported higher quarterly revenue but remains highly leveraged and subject to going concern risk for the three months ended June 30, 2026. Revenue rose to $4.28 million from $3.87 million a year earlier, driven mainly by technology fees of $4.17 million. Gross profit increased to $3.53 million, while operating income was modest at $158,068.
After heavy interest, accretion and derivative-related expenses, the company recorded a net loss attributable to common stockholders of $1.07 million versus $0.75 million in the prior-year quarter, and a basic and diluted loss per share of $0.046. Operating cash flow improved to a positive $507,227, but cash on hand was only $466,503 at quarter-end.
The balance sheet is highly strained: total assets were $6.02 million against total liabilities of $39.72 million, resulting in a stockholders’ deficit of $35.41 million and a working capital deficiency of $31.75 million. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and expects to rely on continued revenue growth plus additional debt and equity financings.
Biotricity Inc. reported higher revenue and narrower losses but remains under significant financial strain. For the nine months ended December 31, 2025, revenue rose to $11.7 million from $10.1 million, with gross profit increasing to $9.5 million. Net loss attributable to common stockholders improved to $2.7 million from $9.9 million, reflecting lower operating expenses and reduced accretion and derivative costs.
Despite this progress, the balance sheet is highly leveraged. Total assets were $5.7 million against $38.2 million in total liabilities, producing a stockholders’ deficiency of $34.2 million and a working capital deficit of $18.8 million. Cash was only $256,357, and operating activities used $0.7 million of cash over nine months.
Management states that recurring losses, a large accumulated deficit of $142.1 million, and liquidity constraints raise substantial doubt about Biotricity’s ability to continue as a going concern. The company expects to fund operations through continued revenue growth and additional equity and debt financings, but there is no assurance it can secure sufficient capital or avoid further dilution.
Biotricity (BTCY) filed its quarterly report for the period ended September 30, 2025. The company grew revenue to $3,885,795 for the quarter (from $3,266,846) and $7,759,788 for the six months (from $6,468,589). Gross profit rose to $3,181,498 in the quarter, and Biotricity posted operating income of $273,819 compared with a prior-year operating loss. Net loss narrowed to $(690,913) for the quarter and $(1,362,890) year‑to‑date.
Liquidity remains tight with cash of $308,460 and total liabilities of $37,984,860, resulting in a stockholders’ deficit of $(33,412,378). Management disclosed a working capital deficiency of $18,077,790 and stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern. As of November 13, 2025, there were 27,797,711 common shares outstanding, plus 160,672 exchangeable shares, equivalent to 27,958,383 voting securities.